Japan Reimburses Zolbetuximab, To Cut Price Of Imfinzi, Others
Impact Of Cost Rules, CEA
The first-in-class anti-CLDN 18.2 antibody zolbetuximab will face cost-effectiveness assessment in Japan in the near future, as the country applies stricter reimbursement pricing policies to gain transparency in expenditure through its healthcare reimbursement structure.
